Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

Boomerang Medical Raises $15M in Series A Financing

Returning investor Arboretum Ventures, joined by Hatteras Venture Partners, to fuel Boomerang Medical’s accelerated clinical and regulatory progress.

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Boomerang Medical, a women-led bioelectronic medicine company, today announced the closing of a $15 million Series A financing led by existing investor Arboretum Ventures and new investor Hatteras Venture Partners.

This round brings Boomerang’s total funding to $18 million to date. Boomerang will use the proceeds from the financing to advance clinical studies on neuromodulation for the treatment of autoimmune diseases, with an initial focus on Inflammatory Bowel Disease (IBD).

In conjunction with the Series A financing, Jeff Terrell, General Partner of Hatteras Venture Partners, has joined the Boomerang Board of Directors.

Boomerang Medical Raises $15M in Series A Financing
Heather Simonsen, CEO, Boomerang Medical

“We are thankful for the support of our new and existing investors as we look to expand device-oriented treatment options for people with autoimmune diseases,” said Heather Simonsen, President and Chief Executive Officer of Boomerang Medical. “We are especially proud to announce this financing as a woman-led company, after watching the proportion of venture funding dollars drop from 2.8 percent in 2019 to 1.9 percent thus far in 2022 for companies with a female at the helm, a decline we are helping to reverse.”

“Heather and her team, with strong support from Fogarty Innovation, have reached critical milestones in a very short amount of time, culminating in their recent approval by the Food and Drug Administration to commence the Boomerang Clinical Trial for patients with IBD,” said Jeff Terrell, General Partner, Hatteras Venture Partners. “Hatteras is delighted to support Boomerang’s efforts to develop novel therapies in this area of significant unmet clinical need.”

It is estimated that more than 50 million people in the U.S. have an autoimmune disease, accounting for an annual burden to the overall healthcare system of more than $100 billion. One of the most prevalent and costly is Inflammatory bowel disease (IBD), including its most common forms: Crohn’s disease and ulcerative colitis. The onset of IBD usually occurs in young adulthood, is a lifelong condition, and affects nearly all aspects of living—including patients’ private, occupational and social lives. Research over the past 20 years has shown that stimulating certain nerve pathways may help regulate an overactive immune response in people with IBD and other autoimmune diseases.

Tom Shehab, MD, Managing Partner at Arboretum Ventures added, “The seasoned team at Boomerang is well-suited to advance its device-oriented approach with strong potential to address historically hard-to-treat autoimmune conditions. This investment reflects our belief in the Boomerang platform and the company’s ability to execute towards their vision. We look forward to supporting the team in its clinical efforts and working to combat the increasing incidence of Inflammatory Bowel Disease.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine